Publication date: Sep 28, 2024
With the release of the coronavirus disease 2019 (COVID-19) pandemic in late 2022 in China, the number of people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) roared, including neonatal cases. However, there were few studies on neonatal COVID-19, especially multi-center case reports. This study aimed to explore clinical characteristics and short-term outcomes of neonatal COVID-19 in China. We reviewed 187 cases of neonatal COVID-19 between December 11, 2022, and January 12, 2023. The diagnosis was assessed by symptoms, laboratory tests, X-ray manifestations, and diagnosis code. Clinical characteristics and outcomes were evaluated. In 187 neonatal cases with COVID-19, 84 (44. 9%) had severe SARS-CoV-2 infection. Most patients had confirmed exposure to SARS-CoV-2. Fever and respiratory symptoms were common (75. 4% and 71. 7%, respectively). Severe patients were more likely to have high alanine transaminase (ALT) (> 40U/L) (11. 9% vs. 3. 9%) and high N-terminal pro-brain natriuretic peptide (NT-proBNP) (> 2000pg/mL) (38. 0% vs. 19. 6%), compared with nonsevere ones (P
Open Access PDF
| Concepts | Keywords |
|---|---|
| China | China |
| Coronavirus | Coronavirus disease 2019 |
| Natriuretic | COVID-19 |
| Severe | Female |
| Humans | |
| Infant, Newborn | |
| Male | |
| Neonate | |
| Retrospective Studies | |
| SARS-CoV-2 | |
| Severe |